The Food and Drug Administration approved Alnylam’s drug to treat a rare and deadly heart disease on Thursday, allowing the entry of a new type of medicine in a market dominated by Pfizer’s blockbuster Vyndaqel.
Alnylam is banking on the success of the drug, chemically called vutrisiran, to reach profitability and invest in future treatments. Its drug will compete in the market for transthyretin amyloid cardiomyopathy (ATTR-CM) treatments, which is expected to cross $11 billion in revenues by 2032, according to Global Market Insights.
The injectable drug, Amvuttra, was approved to treat adult patients with ATTR-CM, in which faulty transthyretin proteins accumulate in the heart, potentially causing the organ to fail….